These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
766 related articles for article (PubMed ID: 12467491)
1. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. Watson GS; Craft S CNS Drugs; 2003; 17(1):27-45. PubMed ID: 12467491 [TBL] [Abstract][Full Text] [Related]
2. Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis. Watson GS; Craft S J Neurol Sci; 2006 Jun; 245(1-2):21-33. PubMed ID: 16631207 [TBL] [Abstract][Full Text] [Related]
3. Metabolic and additional vascular effects of thiazolidinediones. Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315 [TBL] [Abstract][Full Text] [Related]
4. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Chen Z; Zhong C Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509 [TBL] [Abstract][Full Text] [Related]
5. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update. Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284 [TBL] [Abstract][Full Text] [Related]
6. Impaired insulin signaling and the pathogenesis of Alzheimer's disease. Revill P; Moral MA; Prous JR Drugs Today (Barc); 2006 Dec; 42(12):785-90. PubMed ID: 17285151 [TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones--tools for the research of metabolic syndrome X. Komers R; Vrána A Physiol Res; 1998; 47(4):215-25. PubMed ID: 9803467 [TBL] [Abstract][Full Text] [Related]
8. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. Jiang Q; Heneka M; Landreth GE CNS Drugs; 2008; 22(1):1-14. PubMed ID: 18072811 [TBL] [Abstract][Full Text] [Related]
9. Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications. Tumminia A; Vinciguerra F; Parisi M; Frittitta L Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30355995 [TBL] [Abstract][Full Text] [Related]
10. Ameliorating effect of anti-Alzheimer's drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer's disease. Ahmed AS; Elgharabawy RM; Al-Najjar AH Exp Biol Med (Maywood); 2017 Jul; 242(13):1335-1344. PubMed ID: 28534431 [TBL] [Abstract][Full Text] [Related]
11. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Watson GS; Cholerton BA; Reger MA; Baker LD; Plymate SR; Asthana S; Fishel MA; Kulstad JJ; Green PS; Cook DG; Kahn SE; Keeling ML; Craft S Am J Geriatr Psychiatry; 2005 Nov; 13(11):950-8. PubMed ID: 16286438 [TBL] [Abstract][Full Text] [Related]
12. Glitazones: clinical effects and molecular mechanisms. Stumvoll M; Häring HU Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692 [TBL] [Abstract][Full Text] [Related]